Akebia Therapeutics (AKBA) Free Cash Flow Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Free Cash Flow Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -85.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.85% |
| Mar 31, 2026 | -61.38% |
| Dec 31, 2025 | 853.42% |
| Sep 30, 2025 | 490.47% |
| Jun 30, 2025 | 346.85% |
| Mar 31, 2025 | 32.13% |
| Dec 31, 2024 | -164.99% |
| Sep 30, 2024 | 53.21% |
| Jun 30, 2024 | -239.75% |
| Mar 31, 2024 | 1.50% |
| Dec 31, 2023 | 110.73% |
| Sep 30, 2023 | -164.79% |
| Jun 30, 2023 | 126.17% |
| Mar 31, 2023 | -15.27% |
| Dec 31, 2022 | 12.94% |
| Sep 30, 2022 | 139.15% |
| Jun 30, 2022 | 59.22% |
| Mar 31, 2022 | 74.56% |
| Dec 31, 2021 | -132.25% |
| Sep 30, 2021 | -78.87% |